Brief: Provectus Biopharmaceuticals Provides Updated Data On Cancer Immunotherapy Pv-10
13/11/2023 14:28
Nov 13 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATED DATA ON
CANCER
IMMUNOTHERAPY PV-10 FOR METASTATIC UVEAL MELANOMA
Source text for Eikon: ID:nGNX7QHVCy
Further company coverage: PVCT.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting